Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:BNTC NASDAQ:IVVD NASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$15.04-0.9%$15.65$7.08▼$17.49$311.07M0.7760,958 shs46,346 shsBNTCBenitec Biopharma$13.91+1.0%$12.33$8.06▼$17.15$347.56M0.4337,857 shs31,547 shsIVVDInvivyd$1.04+1.0%$0.76$0.35▼$2.74$116.90M0.5512.96 million shs2.95 million shsPRTAProthena$8.39+1.5%$7.23$4.32▼$22.71$441.41M-0.041.14 million shs1.19 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-0.92%-2.78%-2.21%+26.92%+20.22%BNTCBenitec Biopharma+1.02%+8.16%+19.71%-8.31%+54.90%IVVDInvivyd+0.97%+19.54%+42.86%+12.42%+22.09%PRTAProthena+1.45%-1.99%+20.89%+65.81%-60.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.714 of 5 stars0.85.00.00.02.30.00.6BNTCBenitec Biopharma1.6527 of 5 stars3.61.00.00.02.50.80.0IVVDInvivyd3.9274 of 5 stars3.65.00.00.02.64.20.6PRTAProthena3.3042 of 5 stars4.23.00.00.02.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 1.50Reduce$12.00-20.21% DownsideBNTCBenitec Biopharma 3.13Buy$26.0086.92% UpsideIVVDInvivyd 3.25Buy$3.18206.09% UpsidePRTAProthena 2.33Hold$19.75135.40% UpsideCurrent Analyst Ratings BreakdownLatest IVVD, AMRN, PRTA, and BNTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$29.00 ➝ $11.008/28/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$81.00 ➝ $15.008/28/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.008/27/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.008/25/2025AMRNAmarinZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/25/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $1.008/15/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $3.008/5/2025PRTAProthenaRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$18.00 ➝ $10.008/5/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.008/5/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.007/7/2025BNTCBenitec BiopharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M1.36N/AN/A$22.48 per share0.67BNTCBenitec Biopharma$80K4,564.22N/AN/A$4.68 per share2.97IVVDInvivyd$25.38M4.92N/AN/A$0.36 per share2.89PRTAProthena$135.16M3.34N/AN/A$6.03 per share1.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$82.18M-$3.67N/AN/AN/A-47.22%-21.18%-15.00%10/29/2025 (Estimated)BNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-38.26%-35.71%9/25/2025 (Estimated)IVVDInvivyd-$169.93M-$0.92N/A9.45N/A-238.33%-177.89%-90.96%11/13/2025 (Estimated)PRTAProthena-$122.31M-$5.64N/AN/AN/A-2,929.30%-62.17%-54.43%11/11/2025 (Estimated)Latest IVVD, AMRN, PRTA, and BNTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q4 2025BNTCBenitec Biopharma-$0.24N/AN/AN/AN/AN/A8/14/2025Q2 2025IVVDInvivyd-$0.04-$0.12-$0.08-$0.12$23.16 million$11.79 million8/4/2025Q2 2025PRTAProthena-$1.11-$1.86-$0.75-$2.34$5.36 million$4.42 million7/30/2025Q2 2025AMRNAmarin-$0.66-$0.03+$0.63-$0.03$45.45 million$72.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.262.34BNTCBenitec Biopharma0.0114.8014.80IVVDInvivydN/A1.331.33PRTAProthenaN/A5.685.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%BNTCBenitec Biopharma52.19%IVVDInvivyd70.36%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipAMRNAmarin1.96%BNTCBenitec Biopharma1.30%IVVDInvivyd25.40%PRTAProthena9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.68 million20.28 millionOptionableBNTCBenitec Biopharma2026.25 million25.91 millionNo DataIVVDInvivyd100120.14 million89.63 millionOptionablePRTAProthena13053.83 million48.88 millionOptionableIVVD, AMRN, PRTA, and BNTC HeadlinesRecent News About These CompaniesProthena (NASDAQ:PRTA) Price Target Lowered to $11.00 at JMP Securities1 hour ago | americanbankingnews.comProthena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?September 3 at 12:36 PM | zacks.comArmistice Capital LLC Sells 40,000 Shares of Prothena Corporation plc $PRTASeptember 2 at 8:12 AM | marketbeat.comNuveen LLC Acquires Shares of 149,961 Prothena Corporation plc $PRTASeptember 1 at 3:32 AM | marketbeat.comSiren L.L.C. Raises Stake in Prothena Corporation plc $PRTAAugust 31, 2025 | marketbeat.comPiper Sandler Cuts Prothena (NASDAQ:PRTA) Price Target to $15.00August 31, 2025 | americanbankingnews.comPiper Sandler Has Lowered Expectations for Prothena (NASDAQ:PRTA) Stock PriceAugust 30, 2025 | marketbeat.comProthena's (PRTA) Buy Rating Reiterated at Chardan CapitalAugust 30, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Decreases Holdings in Prothena Corporation plc $PRTAAugust 30, 2025 | marketbeat.comProthena provides mixed update on PRX012August 30, 2025 | thepharmaletter.comTChardan Capital Reaffirms Buy Rating for Prothena (NASDAQ:PRTA)August 30, 2025 | americanbankingnews.comProthena Corporation plc: Prothena to Participate in the Cantor Fitzgerald Global Healthcare ConferenceAugust 28, 2025 | finanznachrichten.deProthena to Participate in the Cantor Fitzgerald Global Healthcare ConferenceAugust 28, 2025 | businesswire.comProthena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical ProgramAugust 27, 2025 | businesswire.comWellington Management Group LLP Acquires 68,652 Shares of Prothena Corporation plc $PRTAAugust 25, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Stock Passes Below 200 Day Moving Average - Time to Sell?August 24, 2025 | marketbeat.comProthena Corporation plc (NASDAQ:PRTA) Receives Consensus Recommendation of "Hold" from AnalystsAugust 15, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell?August 14, 2025 | marketbeat.comCitizens JMP Remains a Buy on Prothena (PRTA)August 9, 2025 | theglobeandmail.comFY2026 EPS Estimates for Prothena Lifted by Chardan CapitalAugust 9, 2025 | marketbeat.comCantor Fitzgerald Increases Earnings Estimates for ProthenaAugust 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIVVD, AMRN, PRTA, and BNTC Company DescriptionsAmarin NASDAQ:AMRN$15.04 -0.14 (-0.92%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$14.82 -0.22 (-1.43%) As of 09/3/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Benitec Biopharma NASDAQ:BNTC$13.91 +0.14 (+1.02%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$13.90 -0.02 (-0.11%) As of 09/3/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Invivyd NASDAQ:IVVD$1.04 +0.01 (+0.97%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$1.03 -0.01 (-0.48%) As of 09/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Prothena NASDAQ:PRTA$8.39 +0.12 (+1.45%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$8.39 0.00 (0.00%) As of 09/3/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
